MOTS-c Therapy: Complete Guide
MOTS-c (Mitochondrial Open Reading Frame of the 12S rRNA-c) is a 16-amino-acid peptide encoded within mitochondrial DNA — one of the few known mitochondrial-derived peptides with systemic hormonal effects. Discovered in 2015 at USC, MOTS-c acts as an exercise mimetic, improving metabolic flexibility, insulin sensitivity, and skeletal muscle function. Circulating MOTS-c declines sharply with age, and supplementation has become a pillar of longevity-focused peptide protocols alongside NAD+ and epithalon.
Fact-checking at PeptideProbe is editorial, not clinical. Our editors check claims, dosing figures, and trial results against primary sources; they are not licensed clinicians and do not provide medical review. Nothing here is medical advice — talk to a qualified healthcare provider before starting any therapy.
What is MOTS-c?
What Is MOTS-c?
MOTS-c (Mitochondrial Open Reading Frame of the 12S rRNA-c) is a 16-amino-acid peptide encoded within mitochondrial DNA — making it one of the few mitochondrial-derived peptides with systemic hormonal effects. Discovered in 2015 by researchers at the University of Southern California, MOTS-c acts as an exercise mimetic, improving metabolic flexibility, insulin sensitivity, and skeletal muscle function.
Why MOTS-c Matters for Aging
Circulating MOTS-c levels decline sharply with age. This decline correlates with reduced metabolic flexibility, insulin resistance, and increased visceral adiposity — hallmarks of metabolic aging. MOTS-c supplementation has emerged as a pillar of longevity-focused peptide protocols alongside NAD+ precursors and epithalon, with the mechanistic rationale of restoring a signaling molecule whose natural levels diminish.
Current Status
MOTS-c is a research peptide and is not FDA-approved for any indication. FDA's July 2026 briefing document states that neither MOTS-c free base nor MOTS-c acetate is a component of an FDA-approved drug. On July 23, 2026, the FDA Pharmacy Compounding Advisory Committee voted to recommend MOTS-c-related bulk drug substances (MOTS-c free base and MOTS-c acetate) for the 503A Bulks List. That recommendation is advisory only; it is not FDA approval and did not itself change what a patient can legally receive from a compounding pharmacy. FDA's own briefing materials had proposed that MOTS-c free base and MOTS-c acetate, along with the other six peptide families reviewed at the July 23–24 meeting, not be included. For this to affect routine patient access, FDA would still need to make a final determination and add the relevant bulk drug substance to the 503A Bulks List through notice-and-comment rulemaking.
How MOTS-c Works
Mitochondrial-Derived Signaling
Unlike nuclear-encoded peptides, MOTS-c is encoded by mitochondrial DNA and translated within the mitochondrion itself. It is then exported from mitochondria into the cytoplasm and bloodstream, where it acts as a systemic metabolic hormone.
AMPK Activation
MOTS-c's primary mechanism is activation of AMP-activated protein kinase (AMPK) — the cellular energy sensor that responds to low ATP by triggering glucose uptake, fatty acid oxidation, and mitochondrial biogenesis. AMPK activation is a major pathway through which exercise and caloric restriction produce metabolic benefits; MOTS-c mimics this activation pharmacologically.
Folate Cycle and Methionine Metabolism
MOTS-c modulates the folate-methionine cycle, affecting one-carbon metabolism that underlies nucleotide synthesis, methylation reactions, and redox balance.
Skeletal Muscle Effects
In skeletal muscle, MOTS-c enhances glucose uptake, promotes fatty acid oxidation, and improves mitochondrial function. It is released from muscle during exercise, suggesting a role as an exercise-induced signaling molecule.
Nuclear Translocation
Recent research shows MOTS-c translocates to the nucleus under metabolic stress, where it regulates expression of stress-response and metabolic genes — a level of sophistication unusual for a mitochondrial peptide.
Benefits & Uses
Benefits Reported in Preclinical and Early Human Studies
- Improved insulin sensitivity and glucose homeostasis in animal models of type 2 diabetes.
- Reduced visceral fat accumulation on high-fat diet in rodent studies.
- Enhanced exercise capacity in aged mice — the "exercise mimetic" effect.
- Skeletal muscle preservation during aging and catabolic conditions.
- Improved mitochondrial biogenesis and function in aged tissues.
- Anti-inflammatory signaling — reduced pro-inflammatory cytokine release in multiple tissue models.
- Metabolic flexibility — improved ability to switch between glucose and fat oxidation as fuel sources.
Human Research
Early human clinical trials in obesity and prediabetes are underway. Clinical practice reports from peptide therapy settings describe improvements in body composition, energy, and recovery from exercise, but controlled human data beyond small pilot studies remain limited.
Clinical Evidence & Research
Discovery and Foundational Research
Lee et al., Cell Metabolism, 2015 — Original identification of MOTS-c as a mitochondrial-derived peptide. Demonstrated AMPK activation, improved insulin sensitivity, and reduced diet-induced obesity in mouse models.
Exercise and Aging Studies
Reynolds et al., Nature Communications, 2021 — Circulating MOTS-c increases with exercise in young adults but this response is blunted in older adults. Supports the hypothesis that age-related MOTS-c decline contributes to metabolic dysfunction.
Muscle and Metabolism
Multiple studies in skeletal muscle cell culture and rodent models demonstrate MOTS-c's role in glucose uptake, fatty acid oxidation, and mitochondrial biogenesis.
Human Pilot Studies
Several small human studies in metabolic syndrome and insulin resistance are ongoing or recently completed. Effect sizes reported are promising but sample sizes are small.
Evidence Quality Summary
Preclinical evidence is strong. Early human evidence is limited but encouraging. Large randomized controlled trials establishing efficacy in specific clinical endpoints have not yet been completed.
Side Effects & Safety
Reported Side Effects
- Injection-site reactions — most common; typically mild.
- Flu-like symptoms — fatigue, mild headache, muscle aches, particularly at higher doses or when first starting.
- Transient hypoglycemia — rare; more likely in diabetic patients on glucose-lowering medications.
- Mild gastrointestinal symptoms — occasionally reported.
Safety Context
In published preclinical and early human studies, MOTS-c has generally been well tolerated at the doses used. As a research peptide without large-scale clinical trial data, the long-term safety profile is not fully characterized. Patients with diabetes or those on insulin/sulfonylureas should have their regimen monitored when starting MOTS-c, given the potential for enhanced glucose uptake.
Unknowns
Effects during pregnancy, breastfeeding, and in pediatric populations are unknown. Interactions with other peptide therapies and with prescription medications are not well studied.
Dosing & Administration
Common Clinical Protocols
MOTS-c dosing protocols are not standardized — they vary by clinic and pharmacy. Representative ranges:
- 5–10 mg subcutaneously 2–3 times per week (most common longevity/metabolic protocol)
- Cycle length: Typically 8–12 weeks on, 2–4 weeks off, though continuous protocols are also used.
- Timing: Often administered on exercise days to align with physiologic MOTS-c release, though non-exercise timing is also used.
Reconstitution
MOTS-c arrives as a lyophilized powder and is reconstituted with bacteriostatic water per the compounding pharmacy's instructions. Reconstituted product is refrigerated and typically used within 14–30 days.
Administration
Subcutaneous injection into the abdomen, thigh, or upper arm with a small-gauge needle. Site rotation is recommended.
Stacking Considerations
In longevity-focused practice, MOTS-c is commonly paired with NAD+ infusions, epithalon, and sometimes SS-31/elamipretide to address complementary aspects of mitochondrial and cellular aging. Stacking strategies vary widely and should be guided by a qualified practitioner.
Find MOTS-c Providers Near You
Browse 5 listed providers offering MOTS-c therapy in our directory. Compare clinics by location, telehealth availability and insurance acceptance.
Browse ProvidersMOTS-c FAQ
Preclinical evidence in rodents shows meaningful metabolic improvements, including in aged animals where MOTS-c has declined. Early human data suggest similar effects on insulin sensitivity and body composition, but it cannot replace the full musculoskeletal, cardiovascular, and psychological benefits of actual exercise. Think of it as complementary to exercise, not a substitute.
Advertised MOTS-c program pricing varies widely by clinic, dose, frequency, and pharmacy relationship, and clinic fees for consultation, monitoring, and follow-up are often additional. Because the July 2026 PCAC recommendation did not change the law by itself, patients should verify current regulatory status before relying on any advertised compounded access.
No. MOTS-c is a research peptide without FDA approval for any indication. On July 23, 2026, PCAC recommended MOTS-c-related bulk drug substances for the 503A Bulks List, but FDA has not completed rulemaking, so that vote did not make compounded MOTS-c approved or automatically lawful. Legitimate clinical research enrollment remains separate from the 503A compounding process.
Both target mitochondrial function but work through different mechanisms. NAD+ (and its precursors NMN, NR) replenishes a coenzyme essential for mitochondrial energy production and sirtuin activation. MOTS-c activates AMPK signaling and acts as an exercise mimetic. They are often stacked in longevity protocols as complementary interventions.
Preclinical data show reduced visceral fat accumulation and improved metabolic flexibility. Early clinical experience reports modest body-composition improvements, particularly in combination with exercise and dietary adjustments. MOTS-c is not a weight-loss drug in the GLP-1 sense — effects are more metabolic-quality than appetite-suppressing.
Most protocols report subjective improvements in energy and exercise recovery within 2–4 weeks. Metabolic marker changes (glucose, insulin sensitivity) typically emerge over 8–12 weeks. Body-composition changes are slower and depend heavily on exercise and dietary alignment.
What MOTS-c is used for
Each of these reviews the evidence for that goal, including where it is weaker than the marketing suggests.
Where to get MOTS-c with a prescription
MOTS-c requires a prescription and medical supervision. Each service below states that a licensed provider reviews your intake and prescribes through a US compounding pharmacy where appropriate. Those are the companies’ own descriptions of how they operate, not findings of ours. Compounded medications are not FDA-approved, and a consultation does not guarantee a prescription.
Some telehealth links below are affiliate links. If you buy through them, we may earn a commission at no extra cost to you. Commission never affects which products or clinics we list, how they are ordered, or what we say about them — see our editorial policy.
Says a board-certified physician reviews each intake and prescribes through a licensed 503A compounding pharmacy where appropriate, and lists a LegitScript certification. Compounded medications are not FDA-approved.
We are not a clinic and do not prescribe. Listing a service here is not a clinical endorsement of it, and you should confirm licensure and pharmacy sourcing yourself before treatment.
Stay Updated
Get notified when new peptide therapy providers join in your area.
Related Peptides
Sources
Primary literature, regulatory filings, and prescribing information behind this guide. External links open in a new tab.
Medical Disclaimer: This content is for informational purposes only and should not be considered medical advice. Always consult with a qualified healthcare provider before beginning any peptide therapy treatment.